Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial-Reference-Cited by-同舟云学术

Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial

Published:2023-09 Issue:9 Volume:23 Page:1020-1030
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Wu Jun-Dong,Li Jing-Xin,Liu Jian,Wang Hao-Meng,Zhou Guang-Hui,Li Jin,Wu Dou,Chen Xiang,Feng Yan,Qi Xiao-Yuan,Wang Xue,Gou Jin-Bo,Ma Tie-Liang,Yang Xiao-Yun,Xu Li-Feng,Wan Peng,Zhu Tao,Wang Zhong-Fang,Zhu Feng-Cai,Wang Ying,Ma Xiaomin

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference24 articles.

1. A global database of COVID-19 vaccinations;Mathieu;Nat Hum Behav,2021

2. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021;Meslé;Euro Surveill,2021

3. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic;Hoffmann;Cell,2022

4. SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons;Rössler;N Engl J Med,2022

5. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates;He;Emerg Microbes Infect,2021

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B);International Journal of Infectious Diseases;2024-09

2. Vaccination against COVID-19 in a post-pandemic era;COVID-19: An Update;2024-09-01

3. Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial;Med;2024-07

4. Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster;The Lancet Infectious Diseases;2024-06

5. Vaccine Effectiveness against SARS-CoV-2 Infection during the Circulation of Alpha, Delta, or Omicron Variants: A Retrospective Cohort Study in a Tertiary Hospital in Serbia;Vaccines;2024-02-18